Asthma; Eosinophilic Clinical Trial
Official title:
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma. Discovering a New Role of an Old Asthma Player: BASEAS STUDY (Basophils in Eosinophilic Asthma)
In this study, investigators want to evaluation of the impact of benralizumab (Fasenra®, Astra Zeneca) on different cell populations, including basophils and innate lymphoid cells, and several biomarkers, such as miRNAs, cadena α dek receptor pra la interleukin % (IL5Rα) and soluble IL5Rα in patients with severe eosinophilic asthma. For this, basophil and innate cells type 2 (ILC2) populations will be monitored in different point-time of treatment: 8 week (V1), 6 months (V2) and 1 year (V3) in blood and sputum samples. Also, follow-up IL5Rα expression on a cell surface of eosinophils, basophils and ILC2 from peripheral blood and sputum of patients treated with or or without benralizumab. Determination of IL5Rα levels will be performed by flow cytometry
For this: 1. Investigators will monitor basophil miRNAs changes with benralizumab analyzing miRNAS profile of isolated basophil before and after benralizumab treatment. 2. Also, in vitro characterization of benralizumab effects on functionality of human basophils (isolated from allergic asthmatic patients) and human cell line KU812, measuring apoptosis, activation, degranulation and histamine release will be performed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
| Completed |
NCT04181190 -
Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
|
||
| Recruiting |
NCT05787678 -
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
|
||
| Completed |
NCT04456270 -
Asthma Control in a Dutch Primary Care Population
|
||
| Not yet recruiting |
NCT05091385 -
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
|
||
| Recruiting |
NCT05078281 -
Patients With Severe Eosinophilic Asthma Treated With Benralizumab
|
||
| Recruiting |
NCT04512521 -
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
|
||
| Recruiting |
NCT05813288 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
|
Phase 3 | |
| Recruiting |
NCT04319705 -
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
|
Phase 4 | |
| Recruiting |
NCT06288516 -
BenRalizumab Effect on Airway Remodeling in Severe asTHma
|
Phase 4 | |
| Active, not recruiting |
NCT03733535 -
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
|
N/A | |
| Not yet recruiting |
NCT05241769 -
The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
|
||
| Not yet recruiting |
NCT04924478 -
Evaluation of Volatile Organic Compounds in Mepolizumab Therapy
|
||
| Recruiting |
NCT05748600 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
|
Phase 3 | |
| Recruiting |
NCT05763121 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
|
Phase 3 | |
| Completed |
NCT03453021 -
Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
|
||
| Active, not recruiting |
NCT04612556 -
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
|
||
| Recruiting |
NCT05404763 -
Mepolizumab and Physical Activity in Severe Asthma
|
||
| Completed |
NCT04710134 -
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
|
Phase 4 | |
| Not yet recruiting |
NCT05144087 -
The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma
|